Clinical Trial

Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation

Study acronym: AD-Sys

Recruiting

Record status

This record was last updated August 21, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Summary

Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if unresponsive to topical treatment. However, not all patients who suffer from atopic dermatitis respond similarly to this treatment. Pattern recognition of immune cells (PRI) is an efficient method to screen patients to allow a more personalized therapy. The main aim of this scientific explorative study is to unravel the changes in peripheral blood immune cell compositions in patients with atopic eczema undergoing dupilumab treatment. This allows the identification of phenotypes of treatment responders and non-responders and possible approaches of treatment modifications for non-responders.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2021-10-20; most recent amendment 2024-08-20.

Trial Details

NCT Number	NCT05098821
Lead Sponsor	Charite University, Berlin, Germany Collaborators: Sanofi, LEO Pharma
Conditions	Atopic Dermatitis
Enrollment	25 participants
Start Date	2019-10-01
Primary Completion	2025-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-08-21